Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00873769 · ClinicalTrials.gov registry record · Phase 1
Staccato Loxapine PK in Smokers and Nonsmokers
A Phase 1 study, sponsored by Alexza Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT00873769 is a Phase 1 study that has completed, run by Alexza Pharmaceuticals. The registered enrollment target is 35 participants.
The verdict
NCT00873769, a Phase 1 study, has completed, sponsored by Alexza Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
The objective of this trial was to assess the pharmacokinetics of a single dose of 10 mg Staccato Loxapine administered to smokers compared to nonsmokers.
Interventions
- DRUG Inhaled Loxapine 10 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2009-04 |
| Est. Completion | 2009-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00873769
The ClinicalTrials.gov registry entry for NCT00873769 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexza Pharmaceuticals, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Inhaled Loxapine 10 mg is the first listed.
NCT00873769 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00873769 about?
NCT00873769 is a clinical study titled "Staccato Loxapine PK in Smokers and Nonsmokers". The objective of this trial was to assess the pharmacokinetics of a single dose of 10 mg Staccato Loxapine administered to smokers compared to nonsmokers.
What is the current status of trial NCT00873769?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2009-04. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00873769?
The interventions under investigation include: Inhaled Loxapine 10 mg (DRUG).
Who is sponsoring clinical trial NCT00873769?
This trial is sponsored by Alexza Pharmaceuticals, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.